Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 May;28(167):341-4.

[Antiphospholipid syndrome and the kidney diseases]

[Article in Polish]
  • PMID: 20568393
Editorial

[Antiphospholipid syndrome and the kidney diseases]

[Article in Polish]
Maria Majdan. Pol Merkur Lekarski. 2010 May.

Abstract

Antiphospholipid syndrome (APS) is the most common connective tissue disease (CTD) in man. Renal involvement in APS is poorly recognized. The renal manifestations of APS may result from thrombosis occurring at any location within the renal vasculature. The clinical syndromes of renal involvement in APS includes renal artery stenosis, arterial hypertension, APS nephropathy--with variable degrees of severity, extension and chronic microangiopathy, renal vein thrombosis, renalfailure, allograft vascular thrombosis. Clinical symptoms of APS includes hypertension, nephritic or nephrotic syndrome, acute renal insufficiency, chronic kidney disease and reduced survival of renal allografts. Recently a new subset of the APS is proposed--microangiopathic antiphospholipid syndrome (MAPS) comprising those patients presenting with thrombotic microangiopathy and antiphospholipid antibodies. Effective, full anticoagulation is a treatment of choice in any patients with APS and renal involvement.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources